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FGF21 mimetics are a promising therapeutic tool, believed to exert their anti-obesity effect partly through
browning of white fat. Ve´niant et al. (2015) and Samms et al. (2015) present evidence arguing against fat
browning as the primary mechanism causal to weight loss following FGF21-based treatment in mice.Fibroblast growth factor 21 (FGF21) is a
master regulator of substrate turnover
and orchestrates crosstalk between liver,
white adipose tissue (WAT), brown adi-
pose tissue (BAT), skeletal muscle, and
pancreas. Pharmacologic FGF21 re-
verses obesity, diabetes, dyslipidemia,
and hepatic steatosis in rodents and
monkeys, seeding hopes that FGF21-
based therapies could become a powerful
weapon to combat the metabolic syn-
drome. As FGF21 is a potent inducer of
uncoupling protein 1 (UCP1) in WAT,
WAT browning has been proposed to
underlie FGF21-mediated metabolic ben-
efits. Two recent publications in Cell
Metabolism (Ve´niant et al., 2015) and
Cell Reports (Samms et al., 2015) dissect
the inter-dependence between WAT
browning and therapeutic actions of
FGF21-based treatment, concluding that
the pharmacological effects of FGF21
are to a large extent independent from
WAT browning.
Both groups followed the same overall
experimental paradigm and first com-
pared interscapular BAT (iBAT) and
inguinal WAT (igWAT) in mice at 21C
and/or thermoneutrality before and
after FGF21 treatment, either with a
long-acting FGF21 analog (FGF21-Fc)
(Ve´niant et al., 2015) or hFGF21 infusion
(Samms et al., 2015). As BAT activity is
not required at thermoneutrality, iBAT
showed expected signs of BAT whitening
in mice at thermoneutrality. Following
FGF21 treatment, UCP1 was upregulated
in iBAT of 21C-housed mice, and whit-
ened iBAT of mice at thermoneutrality
regained a uniform BAT phenotype. Sig-
nificant igWAT browning with UCP1
protein induction was only observed in
mice at 21C. Despite differences in
igWAT browning extent, FGF21 treat-ment, however, induced similar increase
in energy expenditure without altering
food intake, generating similar weight
loss and glycemic/lipid improvement at
both temperatures. The authors then
repeated experiments at thermoneutrality
using UCP1-knockout (KO) mice. In mice
treated with FGF21-Fc, energy expendi-
ture enhancement was fully preserved
without alteration in food intake (Ve´niant
et al., 2015). In contrast, hFGF21-infused
mice manifested a blunted energy expen-
diture elevation, but food intake was
decreased (Samms et al., 2015). Resul-
tant weight loss and glycemic/lipid bene-
fits were similar to wild-type animals.
Collectively, these findings led to the pro-
posal that WAT browning and UCP1 are
not required for pharmacological effects
of FGF21 treatment.
These intriguing studies interrogating
the mechanisms of FGF21-mediated
metabolic benefits raise many questions.
First, if WAT browning and/or UCP1 are
not involved in weight loss, what are
the precise mechanisms of FGF21-
induced benefits? Second, given the
remarkable efficacy of FGF21 in amelio-
rating dysmetabolism in animals, why
were effects of FGF21 analog only
modest in humans (Gaich et al., 2013)?
Finally, in a broader context, if WAT
browning is merely an epiphenomenon
of FGF21 treatment, does this smother
the excitement over WAT browning as
an anti-obesity strategy?
Recent studies have unveiled a func-
tional BAT/WAT axis in mice. BAT paucity
induces compensatory WAT browning
sufficient tomaintain resistance to obesity
(Schulz et al., 2013), and marked WAT
browning emerges in BAT-ablated mice
to restore FGF21-mediated glycemic im-
provement (Emanuelli et al., 2014). Thus,Cell MetabolismBAT-WAT crosstalk exerts determinative
in vivo influence, indicating the need to
consider BAT status when assessing the
browning phenomenon. As iBAT was
‘‘whitened’’ in animals at thermoneutrality
pre-treatment, FGF21 induced browning
of whitened iBAT, despite decreased
browning of igWAT (Ve´niant et al., 2015;
Samms et al., 2015). Thermogenic effects
of augmented iBAT could exceed igWAT
browning because of greater UCP1 con-
tent (Nedergaard and Cannon, 2014),
which implicates a browning hierarchy
with browning of whitened iBAT poten-
tially overshadowing igWAT browning. In
this regard, the observed similarity in
metabolic benefits following FGF21 treat-
ment at 21C versus thermoneutrality
may be interpreted as congruent to
‘‘the sum of all browning’’ (i.e., browning
of whitened iBAT + browning of igWAT),
and total browning is required for
maximum FGF21 pharmacological effi-
cacy (Figure 1).
So why were FGF21-mediated benefits
preserved in the absence of UCP1?
FGF21-Fc recapitulated metabolic bene-
fits primarily through energy expenditure
enhancement. This represents UCP1-in-
dependent thermogenesis, ascribed to
multiorgan mitochondrial PGC-1a enrich-
ment (Ve´niant et al., 2015), as distin-
guished fromUCP1-dependent pathways
(i.e., WAT browning) in wild-type animals.
In contrast, UCP1-independent thermo-
genesis was blunted in mice treated with
hFGF21 infusion, and decreased food
intake contributed to total weight loss
(Samms et al., 2015). These findings
suggest the recruitment of UCP1-inde-
pendent thermogenesis and appetite
suppression may be FGF21 formulation
dependent. FGF21 is known to poten-
tiate torpor and fasting centrally. Since21, June 2, 2015 ª2015 Elsevier Inc. 795
Figure 1. Schematic Diagram Illustrating Interplay between Central/Peripheral FGF21
Actions, Thermogenesis, iBAT, and igWAT
The efficacy of FGF21 therapeutics is mediated via (1) UCP1-dependent thermogenesis (i.e., igWAT
browning + re-browning of whitened iBAT resulting in overall boosting of whole-body BAT function), (2)
UCP1-independent thermogenesis (e.g., stimulation of multi-organ mitochondrial biogenesis and PGC-
1a enrichment), and (3) central nervous system (CNS) mechanisms.
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PreviewshFGF21 can enter the central nervous
system (CNS), centrally acting hFGF21
may quench thermogenesis and appetite.
These torpid and anorexic signals may
have been masked by FGF21-boosted
UCP1-dependent thermogenesis and
orexigenic compensation in wild-type
animals. It remains to be determined
whether FGF21-Fc crosses the blood-
brain barrier, and it is possible that
FGF21 analog design could be trading
CNS penetrance for superior peripheral
pharmacokinetics at the expense of
attenuated appetite-suppressive bene-
fits. Future studies of FGF21 analogs
should address their central versus pe-
ripheral actions on appetite versus energy
expenditure.
In a broader context, how do these
findings shape the prospect of FGF21-
based therapy in humans? UCP1-KO
mice represent an extreme phenotype in
which alternative thermogenic mecha-
nisms become activated as adaptation
to UCP1 deficiency (Feldmann et al.,
2009). The recruitability of UCP1-inde-796 Cell Metabolism 21, June 2, 2015 ª2015pendent thermogenesis by FGF21 in hu-
mans is unclear, and human BAT (hBAT)
possesses mixed features of classic BAT
and brite/beige fat (Jespersen et al.,
2013), indicating that modern humans
closely resemble mice at thermoneutral-
ity. hBAT is therefore more similar to
brown-able ‘‘whitened iBAT’’ or igWAT.
Indeed, WAT browning is inducible by
FGF21 in human adipocytes (Lee et al.,
2014) and cold acclimation recruits
hBAT in vivo (Yoneshiro et al., 2013).
Taken together, efficacy of FGF21-based
therapeutics may ultimately hinge on
browning in humans, despite their aston-
ishing versatility in eliciting UCP1-inde-
pendent thermogenesis in UCP1-KO ani-
mals. Since circulating FGF21 increases
in humans following cold exposure, and
FGF21 rise is greater among those with
higher hBAT abundance (Lee et al.,
2014), it is tempting to speculate that
hBAT abundance/responsiveness could
modulate FGF21 effects. A recent clinical
trial of FGF21 analog treatment in humans
did not show significant glycemic benefitsElsevier Inc.(Gaich et al., 2013). Could anti-diabetic
effects be more prominent among
selected individuals with greater hBAT
abundance? It would be interesting to
investigate whether hBAT status in hu-
mans impacts FGF21 analog therapeutic
efficacy in the future.
Overall, these new studies challenge
the view that WAT browning underlies
FGF21-mediated pharmacological ef-
fects. This dissociation may have been
clouded by ‘‘hierarchical browning’’ of
whitened BAT, as the ‘‘sum of all brown-
ing’’ may be responsible, at least partly,
for the efficacy of FGF21 therapeutics.
With multiple FGF21 analogs poised for
clinical trials in the era of hBAT renais-
sance, it will be important to determine
the contribution of hBAT activation and/
or recruitment to the observed effects.REFERENCES
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